FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling to include a new indication and provide longer term (96 week) safety and efficacy data from the GEMINI 1 and 2 trials.
FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling
